Nurix Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is December - November.

Millions USD. Fiscal year is Dec - Nov.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Feb '26 Feb 28, 2026	Nov '25 Nov 30, 2025	Nov '24 Nov 30, 2024	Nov '23 Nov 30, 2023	Nov '22 Nov 30, 2022	Nov '21 Nov 30, 2021
Net Income	-	-264.46	-193.57	-143.95	-180.36	-117.19
Depreciation & Amortization	9.92	18.86	16.43	13.65	10.81	6.08
Stock-Based Compensation	-	37.97	33.93	33.67	28.13	15.8
Other Adjustments	-8.74	-10.23	-11.26	-4.58	0.64	1.83
Change in Receivables	-9.5	-	-	-	6	-6
Changes in Accounts Payable	-0.91	-0.63	5.21	1.61	0.09	1.59
Changes in Accrued Expenses	3.45	17.31	11.82	3.12	7.49	6.22
Changes in Unearned Revenue	-14.83	-36.98	-28.55	19.51	-26.63	14.25
Changes in Other Operating Activities	-0.59	-11.3	-6.88	-4.13	-5.97	-6.94
Operating Cash Flow	-119.51	-249.47	-172.87	-81.08	-159.81	-84.37
Capital Expenditures	-5.79	-14	-9.27	-8.4	-12.24	-5.66
Purchases of Investments	-192.18	-455.69	-707.95	-246.33	-239.37	-348.5
Proceeds from Sale of Investments	296.96	617.54	459.51	323.04	278.81	245.91
Investing Cash Flow	98.99	147.85	-257.71	68.3	27.2	-108.25
Issuance of Common Stock	21.14	238.64	485.68	3.22	117.19	153.88
Repurchase of Common Stock	-	-	-0.02	-	-	-0
Net Common Stock Issued (Repurchased)	21.14	238.64	485.67	3.22	117.19	153.88
Financing Cash Flow	1.89	238.64	485.67	3.22	117.19	153.88
Net Cash Flow	-4.65	137.03	55.37	-9.85	-15.42	-38.73
Free Cash Flow	-125.3	-263.47	-182.14	-89.48	-172.05	-90.03
FCF Margin	-174.56%	-313.73%	-333.91%	-116.23%	-445.42%	-302.61%
Free Cash Flow Per Share	-1.34	-3.04	-2.71	-1.65	-3.54	-2.10
Levered Free Cash Flow	-304.03	-291.2	-204.82	-118.57	-206.82	-101.66
Unlevered Free Cash Flow	-325.2	-313.23	-224.57	-129.69	-210.33	-102.48

SEC Filings: 10-K · 10-Q